Amyotrophic Lateral Sclerosis (ALS)

"Anyone's Life Story" Shows Impact of ALS

ALS — a neuromuscular disease which can cause total paralysis and death within 5 years of diagnosis — often seems to come out of nowhere, striking active and athletic individuals in the prime of life.

ALS: Anyone’s Life Story,” MDA’s special feature for National ALS Awareness Month in May, makes the broad impact of this disease abundantly clear.

ALS Research: Zenvia Improves Emotional Symptoms in ALS

The experimental drug Zenvia, developed by Avanir Pharmaceuticals as a treatment for unwanted laughing/crying spells in ALS, has shown continued promise in lessening the frequency of such episodes in people with amyotrophic lateral sclerosis (ALS).

ALS Research: Zenvia Improves Emotional Symptoms in ALS

The experimental drug Zenvia, developed by Avanir Pharmaceuticals as a treatment for unwanted laughing/crying spells in ALS, has shown continued promise in lessening the frequency of such episodes in people with amyotrophic lateral sclerosis (ALS).

MDA Study Shows Lithium Not Helpful in ALS

An MDA-supported, 10-center trial of more than 100 people with amyotrophic lateral sclerosis (ALS) who took the oral medication lithium carbonate — some in conjunction with the ALS drug riluzole — has shown the drug does not provide benefit for disease progression or survival.

The study also showed that lithium can have concerning side effects, and when taken alone (without riluzole), may actually cause harm.

MDA Study Shows Lithium Not Helpful in ALS

An MDA-supported, 10-center trial of more than 100 people with amyotrophic lateral sclerosis (ALS) who took the oral medication lithium carbonate — some in conjunction with the ALS drug riluzole — has shown the drug does not provide benefit for disease progression or survival.

The study also showed that lithium can have concerning side effects, and when taken alone (without riluzole), may actually cause harm.

Familial ALS Research Update

The state of research in the familial (inherited) form of ALS was the focus of a special one-hour Webinar presented by the ALS Therapy Development Institute (ALS TDI) on March 25, with reports by CEO & Chief Scientific Officer Steve Perrin.

Familial ALS Research Update

The state of research in the familial (inherited) form of ALS was the focus of a special one-hour Webinar presented by the ALS Therapy Development Institute (ALS TDI) on March 25, with reports by CEO & Chief Scientific Officer Steve Perrin.

ALS Research: Disconnecting the Immune System

Blocking a key molecular pathway that the body uses to amplify an immune response has been found to delay disease onset and extend survival in mice with a disease that mimics human amyotrophic lateral sclerosis (ALS), say researchers at the MDA-supported ALS Therapy Development Institute (ALS TDI) in Cambridge, Mass.

ALS Research: Disconnecting the Immune System

Blocking a key molecular pathway that the body uses to amplify an immune response has been found to delay disease onset and extend survival in mice with a disease that mimics human amyotrophic lateral sclerosis (ALS), say researchers at the MDA-supported ALS Therapy Development Institute (ALS TDI) in Cambridge, Mass.

ALS SOD1 Trial: A ‘Watershed Moment’

Isis Pharmaceuticals of Carlsbad, Calif., has begun a phase 1 clinical trial of its experimental compound ISIS-SOD1-Rx in people with familial (inherited) ALS caused by toxic SOD1 protein molecules.

Pages